Factors Contributing to Increases in Prescription Drug Expenditures Borne by National Health Insurance in South Korea

Jo, Jeong Sook; Kim, Young Man; Paek, Kyung Won; Bea, Min Hee; Chun, Ki-Hong; Lee, Soojin

doi:10.3349/ymj.2016.57.4.1016

Cited by 8 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found a decreasing trend in price and an increasing trend in quantity, and this result is similar to that of the previous research that the change of prices had a decreasing effect on drug expenditures ( Kwon et al, 2015 ; Jo et al, 2016 ). This finding appears to be the result of continued policy efforts to reduce drug prices.…”

Section: Discussionsupporting

confidence: 91%

“…For inpatients, the rate of change was −12%, indicating a shift to lower-price drugs, and for outpatients, the rate was 10%, indicating a shift to higher-price drugs. Previous research found that the quantity of drugs contributed to increased prescription drug spending ( Jo et al, 2016 ; Kwon, Kim, et al, 2015 ). Jo et al analyzed data from June 2012 to 2018 and reported that mixed effects accounted for 40–60% within the drug classification category and 30–40% within ingredients ( Jo et al, 2016 ).…”

Section: Discussionmentioning

confidence: 99%

“…Previous research found that the quantity of drugs contributed to increased prescription drug spending ( Jo et al, 2016 ; Kwon, Kim, et al, 2015 ). Jo et al analyzed data from June 2012 to 2018 and reported that mixed effects accounted for 40–60% within the drug classification category and 30–40% within ingredients ( Jo et al, 2016 ). According to this study, the total mixed effect increased by 21%, while it decreased for inpatients.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Determinants of Growth in Prescription Drug Spending Using 2010–2019 Health Insurance Claims Data

2021

View full text Add to dashboard Cite

Background: Despite policies to manage prescription drug spending and ensure accessibility, prescription drug spending has continued to increase in South Korea. Using nationwide claims data, this study analyzed trends in total pharmaceutical expenditures and pharmaceutical expenditures by drug classification.Methods: We conducted a retrospective population-based study using the Korean National Health Insurance claims database from January 2010 through December 2019. Pharmaceuticals were categorized as new drugs, continued drugs, and abandoned drugs. Prescription drug spending was calculated using the components of price and quantity for individual products in successive two-year periods, to obviate the need to consider changes over time.Results: Total pharmaceutical expenditures increased by 54.2% from 2010 to 2019 (from USD 11.3 billion to USD 17.4 billion). The average annual growth rate was 4.9% overall (the 4% rate for continued drugs was decomposed into −3.5% for the price of drugs, 8.0% for the quantity of drugs, and −0.5% for mixed effects, a measure of changes in drug treatment patterns). The trends were generally consistent. Particularly sharp increases in expenditures were found for groups L (antineoplastic and immunomodulating agents), C (cardiovascular system drugs), and A (alimentary tract and metabolism drugs).Conclusions: Since increased prescription drug spending was primarily driven by an increase in the quantity of drugs used, consumer-focused policies to reduce drug use are necessary.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Determinants of Growth in Prescription Drug Spending Using 2010–2019 Health Insurance Claims Data

2021

View full text Add to dashboard Cite

show abstract

“…Medications represent a large proportion of health care spendings [1][2][3][4][5][6][7]. Their use is essential for older adults who suffer from multiple chronic diseases.…”

Section: Introductionmentioning

confidence: 99%

Exploring polypharmacy with artificial intelligence: data analysis protocol

Sirois

Khoury

Durand

et al. 2021

BMC Med Inform Decis Mak

View full text Add to dashboard Cite

Background Polypharmacy is common among older adults and it represents a public health concern, due to the negative health impacts potentially associated with the use of several medications. However, the large number of medication combinations and sequences of use makes it complicated for traditional statistical methods to predict which therapy is genuinely associated with health outcomes. The project aims to use artificial intelligence (AI) to determine the quality of polypharmacy among older adults with chronic diseases in the province of Québec, Canada. Methods We will use data from the Quebec Integrated Chronic Disease Surveillance System (QICDSS). QICDSS contains information about prescribed medications in older adults in Quebec collected over 20 years. It also includes diagnostic codes and procedures, and sociodemographic data linked through a unique identification number for each individual. Our research will be structured around three interconnected research axes: AI, Health, and Law&Ethics. The AI research axis will develop algorithms for finding frequent patterns of medication use that correlate with health events, considering data locality and temporality (explainable AI or XAI). The Health research axis will translate these patterns into polypharmacy indicators relevant to public health surveillance and clinicians. The Law&Ethics axis will assess the social acceptability of the algorithms developed using AI tools and the indicators developed by the Heath axis and will ensure that the developed indicators neither discriminate against any population group nor increase the disparities already present in the use of medications. Discussion The multi-disciplinary research team consists of specialists in AI, health data, statistics, pharmacy, public health, law, and ethics, which will allow investigation of polypharmacy from different points of view and will contribute to a deeper understanding of the clinical, social, and ethical issues surrounding polypharmacy and its surveillance, as well as the use of AI for health record data. The project results will be disseminated to the scientific community, healthcare professionals, and public health decision-makers in peer-reviewed publications, scientific meetings, and reports. The diffusion of the results will ensure the confidentiality of individual data.

show abstract

High-Cost Users of Prescription Drugs: National Health Insurance Data from South Korea

2021

View full text Add to dashboard Cite

Factors Contributing to Increases in Prescription Drug Expenditures Borne by National Health Insurance in South Korea

Cited by 8 publications

References 8 publications

Determinants of Growth in Prescription Drug Spending Using 2010–2019 Health Insurance Claims Data

Determinants of Growth in Prescription Drug Spending Using 2010–2019 Health Insurance Claims Data

Exploring polypharmacy with artificial intelligence: data analysis protocol

High-Cost Users of Prescription Drugs: National Health Insurance Data from South Korea

Contact Info

Product

Resources

About